As the first systemic therapy ever approved by the FDA for autoimmune hair loss, baricitinib works by selective Janus kinase 1 and 2 (JAK1/JAK2) inhibition to quiet the body’s overactive immune attack on hair follicles. The 152-week trial results confirm that among patients who achieved 80% or more scalp hair coverage at one year, an extraordinary 89.1% on the 4 mg dose maintained their full hair regrowth for three continuous years, offering long-term stability and significant mental health improvements for patients worldwide.
What Is It and How Does It Work?
Baricitinib (brand name Olumiant) is a once-daily oral tablet (available in 2 mg and 4 mg doses) approved for adults suffering from severe alopecia areata. Alopecia areata occurs when the body’s immune system mistakenly identifies hair follicles as foreign invaders, deploying inflammatory T-cells to surround the hair bulb and force hair to shed rapidly.
The drug operates through a precise biological process called Oral Selective JAK1/JAK2 Inhibition:
-
The Inflammatory Signal Chain: Immune cells communicate through chemical messengers called cytokines (specifically Interferon-gamma and Interleukin-15). These cytokines rely on internal enzyme “switches”—Janus Kinase 1 (JAK1) and Janus Kinase 2 (JAK2)—to transmit attack signals to the hair follicle.
-
Blocking the Switches: Baricitinib acts like a targeted circuit breaker. When ingested, it binds to and inhibits the JAK1 and JAK2 enzymes, preventing the attack signals from reaching the hair root.
-
Restoring Immune Privilege: By blocking this inflammatory chain reaction, the drug restores the hair follicle’s natural “immune privilege”—a protective shield that protects the root from immune system interference. Freed from cellular stress, dormant follicles re-enter their active growth (anagen) phase and resume producing thick, healthy hair.
The Science: 3-Year (152-Week) Maintenance Results and Quality-of-Life Gains
The long-term results come from the extended follow-up of the BRAVE-AA1 and BRAVE-AA2 Phase 3 clinical trials, which evaluated adult patients with severe hair loss (at least 50% scalp hair loss at baseline). To track regrowth objectively, researchers used the SALT score.
What is the SALT Score?
The Severity of Alopecia Tool (SALT) score is the clinical standard for measuring scalp hair loss.
100 represents 100% total scalp hair loss (complete baldness).
0 represents 0% hair loss (100% full scalp coverage).
A SALT score of 20 or less (SALT ≤ 20) is the benchmark for clinical success, indicating that a patient has regrown 80% or more of their scalp hair.
The 152-week (3-year) continuous treatment data demonstrated exceptional durability and deepening response rates:
-
89.1% Regrowth Maintenance (4 mg dose): Among patients who achieved 80% or more scalp hair coverage (SALT ≤ 20) at Week 52 on the 4 mg daily dose, 89.1% sustained their regrowth at Week 152 (3 full years of continuous treatment).
Read next
Whats the best shampoo for hair loss?
-
83.6% Regrowth Maintenance (2 mg dose): In the 2 mg daily dose cohort, 83.6% of successful responders maintained 80% or more scalp coverage at 3 years.
-
Near-Total Scalp Regrowth (SALT ≤ 10): Over 40% of patients on the 4 mg dose achieved a SALT score of 10 or less at 3 years, representing 90% to 100% complete scalp hair coverage.
-
Deepening Response in Slow Responders: A significant proportion of “late responders”—patients who did not meet the 80% coverage threshold at Year 1—continued to gain hair density during Years 2 and 3 of uninterrupted daily therapy.
-
Psychological and Mental Health Recovery: Because severe hair loss carries a heavy emotional burden, researchers tracked patient-reported health outcomes. Long-term baricitinib treatment produced statistically significant reductions in anxiety and depression scores, directly reflecting the profound psychosocial benefits of sustained hair recovery.
-
Consistent Safety Profile: Safety monitoring over 152 weeks confirmed a well-tolerated profile consistent with previous JAK inhibitor studies, with no new or unexpected safety signals emerging during long-term use.
“These 3-year data from the BRAVE-AA trial program demonstrate the long-term durability of baricitinib in adults with severe alopecia areata. Maintaining hair regrowth over three years is a meaningful outcome for patients living with this challenging autoimmune disease.”
— Eli Lilly Research & Development Clinical Team
When Will It Be Available?
-
Regulatory Status: Baricitinib (Olumiant) is fully approved by the US FDA, the European Medicines Agency (EMA), the UK MHRA, and health authorities globally for adults with severe alopecia areata.
-
Pharmacy Availability: Olumiant is available immediately by prescription at pharmacies worldwide.
How you can benefit from this treatment now
If you are an adult struggling with severe patchy or widespread autoimmune hair loss, the 3-year BRAVE-AA data provides immediate, evidence-based options today:
-
Consult a Dermatologist for a Prescription: Because Olumiant is an FDA-approved prescription drug, schedule an appointment with a dermatologist specializing in hair loss. They can evaluate your SALT score, run standard baseline blood panels (including liver, kidney, and infection screenings), and determine whether the 2 mg or 4 mg daily dose is appropriate for you.
-
Commit to Long-Term Daily Consistency: The 152-week data proves that baricitinib works best when taken consistently over several years. Stopping the medication will cause the JAK1/JAK2 switches to turn back on, allowing immune cells to resume attacking hair roots and triggering hair shedding.
-
Explore Patient Support Programs: Because specialty biological medications can be expensive, Eli Lilly offers patient assistance programs (such as the Olumiant Together Savings Card in the US) to help lower out-of-pocket prescription costs for eligible patients.
Sources: